Bicycle Therapeutics (NASDAQ:BCYC) PT Lowered to $46.00

Bicycle Therapeutics (NASDAQ:BCYCGet Rating) had its target price decreased by analysts at JMP Securities from $70.00 to $46.00 in a research note issued to investors on Wednesday, The Fly reports. The firm presently has a “market outperform” rating on the stock. JMP Securities’ target price points to a potential upside of 60.78% from the company’s previous close.

A number of other brokerages have also issued reports on BCYC. Cowen started coverage on Bicycle Therapeutics in a research report on Wednesday, August 31st. They issued an “outperform” rating on the stock. Cowen started coverage on Bicycle Therapeutics in a research report on Wednesday, August 31st. They set an “outperform” rating on the stock. Barclays started coverage on Bicycle Therapeutics in a research report on Thursday, July 28th. They set an “overweight” rating and a $30.00 price target on the stock. HC Wainwright lowered their price target on Bicycle Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research report on Friday, August 5th. Finally, SVB Leerink boosted their price target on Bicycle Therapeutics from $48.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, August 22nd. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $52.40.

Bicycle Therapeutics Stock Up 10.0 %

Shares of Bicycle Therapeutics stock opened at $28.61 on Wednesday. The business’s 50 day simple moving average is $23.88 and its 200 day simple moving average is $21.54. Bicycle Therapeutics has a 52-week low of $12.08 and a 52-week high of $62.08. The firm has a market cap of $849.03 million, a PE ratio of -8.37 and a beta of 0.76. The company has a debt-to-equity ratio of 0.10, a quick ratio of 9.18 and a current ratio of 9.18.

Institutional Trading of Bicycle Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Great Point Partners LLC boosted its stake in Bicycle Therapeutics by 175.3% in the 1st quarter. Great Point Partners LLC now owns 550,592 shares of the company’s stock valued at $24,160,000 after purchasing an additional 350,592 shares during the period. Tekla Capital Management LLC bought a new stake in shares of Bicycle Therapeutics during the 1st quarter valued at $443,000. Sio Capital Management LLC lifted its position in shares of Bicycle Therapeutics by 1,205.2% during the 2nd quarter. Sio Capital Management LLC now owns 688,989 shares of the company’s stock valued at $11,561,000 after acquiring an additional 636,201 shares during the period. Qube Research & Technologies Ltd bought a new stake in shares of Bicycle Therapeutics during the 1st quarter valued at $386,000. Finally, DekaBank Deutsche Girozentrale lifted its position in shares of Bicycle Therapeutics by 10.0% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 13,200 shares of the company’s stock valued at $562,000 after acquiring an additional 1,200 shares during the period. 76.45% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Company Profile

(Get Rating)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

See Also

The Fly logo

Analyst Recommendations for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.